Foseco India Limited has submitted to the Exchange, the financial results (standalone and consolidated) for the financial year ended December 31, 2025.
FOSECOIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 3.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Foseco India announced audited financial results for the quarter and year ended December 31, 2025, with the Board approving both standalone and consolidated numbers. On a standalone basis, revenue from operations grew about 15% year-on-year to Rs. 604 crore, while net profit rose modestly to Rs. 75.2 crore from Rs. 73 crore. Consolidated revenue jumped around 22.6% to Rs. 643 crore, boosted by the November 2025 acquisition of a 75% stake in Morganite Crucible (India) Limited (MCIL), which was funded through a share swap worth Rs. 638 crore. The Group booked a sizeable exceptional charge of Rs. 21.7 crore (standalone: Rs. 9.3 crore) towards pre-acquisition and regulatory expenses linked to the MCIL deal. Price Waterhouse issued an unmodified (clean) opinion on the financial statements. The Board has recommended a final dividend of Rs. 25 per share (250%) on the Rs. 10 face value, subject to shareholder approval.
The clean audit opinion and strong dividend (250%) are positives for shareholders, but muted standalone profit growth (just ~3%) despite a 15% revenue rise reflects margin pressure and the one-time acquisition-related exceptional cost. Consolidated revenue growth of 22.6% shows inorganic expansion from MCIL is already contributing, though the diluted EPS actually dipped slightly to Rs. 110.46 from Rs. 114.35 because of the enlarged share base post-swap.